Navigation Links
Personalized Stem Cells, Inc. Submits Investigational New Drug (IND) Application for the Treatment of Osteoarthritis with Stem Cells
Date:6/18/2019

Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell company, has submitted an Investigational New Drug (IND) application to the FDA for use of a person’s own adipose-derived stem cells to treat their osteoarthritis. The first clinical trial uses stem cells as a treatment of osteoarthritis in the knee. This IND is the first of several planned clinical trials which will enable qualified PSC-enrolled physicians to provide FDA compliant, regulated quality cell therapy to patients suffering from osteoarthritis. PSC plans to conduct a series of FDA-IND approved clinical trials starting with uses in orthopedics and expanding to other medical conditions in the future.

PSC has contracted with VetStem Biopharma for cGMP stem cell manufacturing for use in Phase I/II human trials by the PSC network of physicians. PSC has also licensed the VetStem patent portfolio and intellectual property for use of adipose-derived regenerative cells.

The current environment of in-office, unregulated manufacturing of stem cells by physicians has come under serious regulatory action by the FDA, FTC, and the Federation of State Medical Boards. It is clear that the only allowed use of stem cells will be through legitimate FDA clinical trials with manufacturing in a controlled FDA inspected, GMP compliant facility. Qualified physicians enrolled in the PSC network will have access to quality manufactured, safety tested cells for use in FDA approved clinical trials. They will also be able to share their experiences with other PSC network physicians in order to better define and implement the highest quality treatment options in the future.

PSC was founded by Robert Harman, DVM, MPVM and Michael Dale, both of whom also co-founded VetStem and are both experienced serial entrepreneurs.

“This is a unique opportunity in history to have a profound influence on the development and adoption of a game-changing medical technology,” says Mr. Dale. “Regenerative medicine may offer help for a wide array of conditions that are not effectively treated with today’s medicines.”

“We believe that we can jumpstart human stem cell therapy using the VetStem GMP manufacturing capabilities, extensive preclinical data, and experience. Mr. Dale will rapidly lead PSC forward with legitimate FDA approved clinical trials,” says Dr. Harman.

About Personalized Stem Cells, Inc.
Personalized Stem Cells was formed in 2018 to advance and legitimize human regenerative medicine. This privately held biopharmaceutical enterprise, based near San Diego (California), offers qualified physicians who enroll, an FDA compliant autologous stem cell product (from patient’s own fat tissue) for use in FDA approved clinical trials. PSC is driving development and adoption of stem cell and regenerative medicine within the FDA-IND process by providing quality manufactured, safety tested cells, and well-defined clinical trials. PSC has licensed a portfolio of over 70 issued patents in the field of regenerative medicine.

Read the full story at https://www.prweb.com/releases/personalized_stem_cells_inc_submits_investigational_new_drug_ind_application_for_the_treatment_of_osteoarthritis_with_stem_cells/prweb16384983.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. VetStem Biopharma, Parent Company of Personalized Stem Cells, is Approved for Stem Cell Manufacturing by the California Department of Public Health
2. A New Kind of Thinking Cap: Worcester Polytechnic Institute Researchers Are Using Brain Imaging to Improve Personalized Learning Environments
3. RSNA: Personalized Treatment Benefits Kidney Cancer Patients
4. PhysIQ Personalized Physiology Analytics (PPA) Wins DPharm Idol 2017
5. Director of Scientific Programs of NIH’s All of Us Research Program to Provide Update at the 9th Annual Personalized & Precision Medicine Conference
6. ACEA Biosciences Announces Collaboration with Memorial Sloan Kettering Cancer Center on Personalized CAR T Cell Therapy
7. ISABS: Personalized Medicine Conference With Nobel Prize Laureates Participation to be Held in Dubrovnik, Croatia
8. Notable Labs Enters into a Collaboration Agreement with IntelliCyt to Develop a Phenotypic Personalized Medicine Platform for Cancer Patients
9. Proove Health Foundation Is Created to Support the Role of Personalized Medicine in Public Health Epidemics
10. IntelliCyt and FIMM Announce a Collaboration to Advance Personalized Medicine in Cancer Treatment
11. Proove Biosciences Highlights Personalized Medicine Technology as an Approach to Reduce Prescription Drug Abuse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... ... June 11, 2019 , ... Veterinary Regenerative Medicine company, ... has announced that their GMP facility for cell production is now approved by ... This is an important milestone for VetStem as it expands into contract cell ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... providing proprietary interest to our methodology, processes, and diagnostic techniques. The patent ... extends Somnology’s IP rights including our proprietary sleep scoring methodology. The approval ...
(Date:5/22/2019)... ... , ... Artemis (formerly Agrilyst), the leading enterprise Cultivation Management Platform ... by Astanor Ventures and Talis Capital with participation from existing ... . The company has raised $11.75m to date and will use the new funding ...
(Date:5/14/2019)... (PRWEB) , ... May 13, 2019 , ... ... built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device and Food ... company website. The redesigned website aims to improve LDA’s ability to communicate directly ...
Breaking Biology Technology:
(Date:7/17/2019)... ... July 18, 2019 , ... Flagship Biosciences, the advanced tissue ... its executive team as Vice President of Operations. Ms. James brings a wealth ... role, Ms. James is responsible for ensuring on-time delivery of all projects by ...
(Date:7/17/2019)... ... July 15, 2019 , ... ... exclusively for Life Sciences and Healthcare companies, announces the availability of new specialty ... and strategic direction to start-up and emerging bio-pharma companies interested in achieving specific ...
(Date:7/17/2019)... CITY, S.D. (PRWEB) , ... July 16, 2019 , ... ... to form, or to detect bone loss before it causes osteoporosis. For South Dakota ... , “This is potentially a game-changer in terms of our ability to monitor ...
Breaking Biology News(10 mins):